{
  "raw_text": "I\n \nam\n \nwriting\n \nto\n \nrequest\n \na\n \nNational\n \nInterest\n \nWaiver\n \nfor\n \nmy\n \nemployment-based\n \nsecond\n \npreference\n \n(EB-2)\n \nimmigrant\n \nvisa\n \npetition.\n \nAs\n \nan\n \nimmunologist\n \nwith\n \nover\n \neight\n \nyears\n \nof\n \nresearch\n \nexperience\n \nin\n \nunderstanding\n \nautoimmune\n \ndiseases\n \nand\n \ndeveloping\n \nnovel\n \ntherapeutic\n \napproaches,\n \nparticularly\n \nin\n \nthe\n \nfield\n \nof\n \nCAR-T\n \ncell\n \ntherapy,\n \nmy\n \nwork\n \nhas\n \nmade\n \nsignificant\n \ncontributions\n \nto\n \nthe\n \nfield\n \nof\n \nimmunology\n \nand\n \nhas\n \nsubstantial\n \nmerit\n \nand\n \nnational\n \nimportance\n \nto\n \nthe\n \nUnited\n \nStates.\n \nBackground\n \nand\n \nExpertise\n \nI\n \nearned\n \nmy\n \nPh.D.\n \nin\n \nImmunology\n \nfrom\n \na\n \nprestigious\n \nresearch\n \nuniversity\n \nin\n \nthe\n \nUnited\n \nKingdom\n \nin\n \n2018,\n \nwhere\n \nmy\n \nresearch\n \nfocused\n \non\n \nunderstanding\n \nthe\n \nrole\n \nof\n \nregulatory\n \nT\n \ncells\n \nin\n \nautoimmune\n \ndiseases.\n \nDuring\n \nmy\n \ndoctoral\n \nstudies,\n \nI\n \ndiscovered\n \na\n \nnovel\n \nsignaling\n \npathway\n \nthat\n \nregulates\n \nT\n \ncell\n \nexhaustion\n \nin\n \nautoimmune\n \nconditions,\n \npublished\n \nas\n \na\n \nfirst-author\n \npaper\n \nin\n \nNature\n \n(2018,\n \nImpact\n \nFactor:\n \n49.962,\n \ncited\n \n847\n \ntimes).\n \nThis\n \ndiscovery\n \nhas\n \nbecome\n \nfundamental\n \nto\n \nunderstanding\n \nT\n \ncell\n \ndynamics\n \nin\n \nboth\n \nautoimmune\n \ndiseases\n \nand\n \ncancer\n \nimmunotherapy.\n \nCurrently,\n \nI\n \nam\n \na\n \nSenior\n \nResearch\n \nScientist\n \nat\n \na\n \nleading\n \nbiomedical\n \nresearch\n \ninstitute\n \nin\n \nthe\n \nUnited\n \nStates,\n \nwhere\n \nI\n \nlead\n \na\n \nteam\n \ninvestigating\n \nnew\n \napproaches\n \nto\n \nenhance\n \nCAR-T\n \ncell\n \ntherapy\n \nefficacy.\n \nMy\n \nmost\n \nsignificant\n \ncontribution\n \nhas\n \nbeen\n \nthe\n \ndevelopment\n \nof\n \na\n \nproprietary\n \nmodification\n \nto\n \nCAR-T\n \ncells\n \nthat\n \naddresses\n \nT\n \ncell\n \nexhaustion\n \nin\n \nsolid\n \ntumors.\n \nThis\n \nbreakthrough\n \nwas\n \npublished\n \nin\n \nCell\n \n(2022,\n \nImpact\n \nFactor:\n \n41.582,\n \ncited\n \n392\n \ntimes),\n \nand\n \nhas\n \nled\n \nto\n \na\n \npatent\n \nthat\n \nis\n \ncurrently\n \nbeing\n \nlicensed\n \nby\n \nthree\n \nmajor\n \npharmaceutical\n \ncompanies.\n \nSubstantial\n \nMerit\n \nand\n \nNational\n \nImportance\n \nMy\n \nresearch\n \naddresses\n \ncritical\n \nchallenges\n \nin\n \nboth\n \nautoimmune\n \ndiseases\n \nand\n \ncancer\n \nimmunotherapy,\n \nwhich\n \ncollectively\n \naffect\n \nmillions\n \nof\n \nAmericans.\n \nThe\n \neconomic\n \nimpact\n \nof\n \ncancer\n \nalone\n \nin\n \nthe\n \nUnited\n \nStates\n \nexceeds\n \n$200\n \nbillion\n \nannually\n \nin\n \nhealthcare\n \ncosts,\n \nwhile\n \nautoimmune\n \ndiseases\n \nadd\n \nanother\n \n$100\n \nbillion\n \nto\n \nthis\n \nburden.\n \nMy\n \nwork\n \nspecifically\n \nfocuses\n \non\n \ndeveloping\n \nmore\n \neffective\n \nCAR-T\n \ncell\n \ntherapies\n \nthat\n \ncould\n \ntransform\n \ntreatment\n \noutcomes\n \nfor\n \npatients\n \nwith\n \nsolid\n \ntumors,\n \nan\n \narea\n \nwhere\n \ncurrent\n \nCAR-T\n \napproaches\n \nhave\n \nshown\n \nlimited\n \nsuccess.\n \nI\n \nhave\n \npublished\n \na\n \nseries\n \nof\n \nhigh-impact\n \npapers\n \nthat\n \nhave\n \nadvanced\n \nour\n \nunderstanding\n \nof\n \nT\n \ncell\n \nbiology\n \nand\n \nits\n \ntherapeutic\n \napplications.\n \nIn\n \nScience\n \nImmunology\n \n(2021,\n \nImpact\n \nFactor:\n \n22.782,\n \ncited\n \n235\n \ntimes),\n \nI\n \ndetailed\n \na\n \nnovel\n \nmechanism\n \nfor\n \npreventing\n \nCAR-T\n \ncell\n \nexhaustion\n \nthrough\n \nthe\n \nmodulation\n \nof\n \nthe\n \nJAK-STAT\n \npathway.\n \nThis\n \nwork\n \nwas\n \nfollowed\n \nby\n \na\n \ncomprehensive\n \nreview\n \nin\n \nNature\n \nReviews\n \nImmunology\n \n(2023,\n \nImpact\n \nFactor:\n \n54.319,\n \ncited\n \n127\n \ntimes),\n \nwhere\n \nI\n \noutlined\n \nthe\n \ncurrent\n \nchallenges\n \nand\n \nfuture\n \ndirections\n \nin\n \nCAR-T\n \ncell\n \ntherapy\n \nfor\n \nsolid\n \ntumors.\n \nThe\n \npractical\n \nimpact\n \nof\n \nmy\n \nresearch\n \nextends\n \nbeyond\n \nacademic\n \npublications.\n \nMy\n \npatented\n \nCAR-T\n \ncell\n \nmodification\n \ntechnology\n \nhas\n \nshown\n \nremarkable\n \nresults\n \nin\n \npreclinical\n \ntrials.\n \nIn\n \nstudies\n \nwith\n \nmurine\n \nmodels\n \nof\n \npancreatic\n \ncancer,\n \nour\n \nmodified\n \nCAR-T\n \ncells\n \ndemonstrated\n \nan\n \n85%\n \nimprovement\n \nin\n \ntumor\n \nreduction\n \ncompared\n \nto\n \nconventional\n \nCAR-T\n \ncells.\n \nThese\n \nresults\n \nhave\n \nattracted\n \n$2.5\n \nmillion\n \nin\n \nresearch\n \nfunding\n \nfrom\n \nthe\n \nNational\n \nInstitutes\n \nof\n \nHealth\n \n(NIH)\n \nand\n \nled\n \nto\n \ncollaborations\n \nwith\n \nleading\n \npharmaceutical\n \ncompanies.\n Well\n \nPositioned\n \nto\n \nAdvance\n \nthe\n \nProposed\n \nEndeavor\n \nMy\n \nunique\n \nposition\n \nto\n \nadvance\n \nthis\n \ncritical\n \nresearch\n \nstems\n \nfrom\n \nmy\n \nspecialized\n \nexpertise\n \nin\n \nT\n \ncell\n \nbiology\n \nand\n \nCAR-T\n \ncell\n \nengineering.\n \nI\n \nhave\n \nestablished\n \na\n \nrobust\n \nresearch\n \nprogram\n \nthat\n \ncombines\n \ncutting-edge\n \nmolecular\n \nbiology\n \ntechniques\n \nwith\n \ninnovative\n \nimmunological\n \napproaches.\n \nMy\n \nlaboratory\n \nhas\n \ndeveloped\n \nproprietary\n \nprotocols\n \nfor\n \nT\n \ncell\n \nengineering\n \nthat\n \nachieve\n \na\n \n40%\n \nhigher\n \nmodification\n \nefficiency\n \nthan\n \nstandard\n \nmethods.\n \nAt\n \nmy\n \ncurrent\n \ninstitution,\n \nI\n \nhave\n \nbuilt\n \na\n \ncollaborative\n \nnetwork\n \nthat\n \nincludes\n \npartnerships\n \nwith\n \nmajor\n \ncancer\n \ncenters\n \nacross\n \nthe\n \nUnited\n \nStates.\n \nThese\n \ncollaborations\n \nprovide\n \naccess\n \nto\n \nclinical\n \nsamples\n \nand\n \nfacilitate\n \nthe\n \ntranslation\n \nof\n \nour\n \nfindings\n \ninto\n \ntherapeutic\n \napplications.\n \nWe\n \nare\n \ncurrently\n \npreparing\n \nfor\n \nPhase\n \nI\n \nclinical\n \ntrials\n \nof\n \nour\n \nmodified\n \nCAR-T\n \ncells,\n \nscheduled\n \nto\n \nbegin\n \nin\n \nearly\n \n2026.\n \nNational\n \nBenefit\n \nMy\n \ncontinued\n \nresearch\n \nin\n \nthe\n \nUnited\n \nStates\n \nwould\n \nsignificantly\n \ncontribute\n \nto\n \nmaintaining\n \nthe\n \nnation's\n \nleadership\n \nin\n \ncellular\n \nimmunotherapy.\n \nThe\n \nCAR-T\n \ncell\n \ntherapy\n \nmarket\n \nis\n \nprojected\n \nto\n \nreach\n \n$20\n \nbillion\n \nby\n \n2027,\n \nand\n \ninnovations\n \nin\n \nthis\n \nfield\n \nare\n \ncrucial\n \nfor\n \nboth\n \neconomic\n \ncompetitiveness\n \nand\n \npublic\n \nhealth.\n \nMy\n \nwork\n \naddresses\n \na\n \ncritical\n \ngap\n \nin\n \ncurrent\n \nCAR-T\n \ncell\n \ntherapy\n \n\u2013\n \nits\n \nlimited\n \nefficacy\n \nin\n \nsolid\n \ntumors\n \n\u2013\n \nwhich\n \ncould\n \npotentially\n \nexpand\n \ntreatment\n \noptions\n \nfor\n \nmillions\n \nof\n \ncancer\n \npatients.\n \nFuture\n \nPlans\n \nAs\n \na\n \nSenior\n \nResearch\n \nScientist\n \nat\n \nmy\n \ncurrent\n \ninstitution,\n \nI\n \nam\n \ndeeply\n \ncommitted\n \nto\n \ncontinuing\n \nmy\n \nwork\n \nin\n \ncellular\n \nimmunotherapy\n \nand\n \nexpanding\n \nour\n \nunderstanding\n \nof\n \nT\n \ncell\n \nbiology.\n \nMy\n \ncurrent\n \nposition\n \nprovides\n \nan\n \nideal\n \nplatform\n \nfor\n \nadvancing\n \nCAR-T\n \ncell\n \ntherapy\n \nresearch,\n \nwith\n \naccess\n \nto\n \nstate-of-the-art\n \nfacilities\n \nand\n \nestablished\n \nclinical\n \npartnerships.\n \nI\n \nhave\n \nrecently\n \nbeen\n \nappointed\n \nas\n \nthe\n \nDirector\n \nof\n \nthe\n \nCellular\n \nEngineering\n \nCore,\n \nwhich\n \nwill\n \nallow\n \nme\n \nto\n \nexpand\n \nour\n \nresearch\n \nprogram\n \nand\n \nmentor\n \nthe\n \nnext\n \ngeneration\n \nof\n \nimmunotherapy\n \nresearchers.\n \nOur\n \nlaboratory\n \nis\n \ncurrently\n \noptimizing\n \nour\n \nnovel\n \nCAR-T\n \ncell\n \ntechnology\n \nfor\n \ndifferent\n \ntypes\n \nof\n \nsolid\n \ntumors,\n \nwith\n \npromising\n \npreliminary\n \nresults\n \nin\n \ncolorectal\n \nand\n \nbreast\n \ncancer\n \nmodels.\n \nIn\n \nparallel,\n \nwe\n \nare\n \ndeveloping\n \na\n \nsimplified\n \nmanufacturing\n \nprocess\n \nthat\n \ncould\n \nreduce\n \nthe\n \nproduction\n \ncost\n \nof\n \nCAR-T\n \ncells\n \nby\n \napproximately\n \n60%,\n \nmaking\n \nthis\n \nrevolutionary\n \ntreatment\n \nmore\n \naccessible\n \nto\n \npatients.\n \nThe\n \ninstitution\n \nhas\n \ndemonstrated\n \nits\n \ncommitment\n \nto\n \nthis\n \nresearch\n \ndirection\n \nby\n \nallocating\n \nadditional\n \nlaboratory\n \nspace\n \nand\n \nresources\n \nfor\n \nour\n \nexpanding\n \nprogram,\n \nand\n \nI\n \nhave\n \nsecured\n \nfunding\n \ncommitments\n \nthat\n \nwill\n \nsupport\n \nour\n \nresearch\n \nthrough\n \n2028.\n \nMy\n \ndedication\n \nto\n \nthis\n \nfield\n \nstems\n \nfrom\n \nseeing\n \nthe\n \ntransformative\n \npotential\n \nof\n \nour\n \nwork\n \nin\n \npreclinical\n \nstudies.\n \nI\n \nplan\n \nto\n \ncontinue\n \nleading\n \ncutting-edge\n \nresearch\n \nin\n \nCAR-T\n \ncell\n \ntherapy\n \ndevelopment\n \nwhile\n \nfostering\n \ncollaborations\n \nwith\n \nmajor\n \ncancer\n \ncenters\n \nand\n \nbiotechnology\n \ncompanies.\n \nThese\n \npartnerships\n \nwill\n \nbe\n \ncrucial\n \nfor\n \ntranslating\n \nour\n \nlaboratory\n \nfindings\n \ninto\n \nclinical\n \napplications\n \nthat\n \ncan\n \nbenefit\n \ncancer\n \npatients\n \nacross\n \nthe\n \nUnited\n \nStates.\n Conclusion\n \nMy\n \nresearch\n \nin\n \nimmunology\n \nand\n \nCAR-T\n \ncell\n \ntherapy\n \nhas\n \ndemonstrated\n \nsubstantial\n \nmerit\n \nand\n \nnational\n \nimportance\n \nthrough\n \nits\n \npotential\n \nto\n \ntransform\n \ncancer\n \ntreatment\n \nand\n \nreduce\n \nhealthcare\n \nburden.\n \nWith\n \nmy\n \nunique\n \nexpertise,\n \nestablished\n \nresearch\n \nprogram,\n \nand\n \ntrack\n \nrecord\n \nof\n \ninnovation,\n \nI\n \nam\n \nwell-positioned\n \nto\n \ncontinue\n \nadvancing\n \nthis\n \nwork.\n \nGranting\n \nme\n \na\n \nNational\n \nInterest\n \nWaiver\n \nwould\n \nallow\n \nme\n \nto\n \ncontinue\n \ncontributing\n \nto\n \nthe\n \nUnited\n \nStates'\n \nleadership\n \nin\n \ncellular\n \nimmunotherapy\n \nand\n \nthe\n \ndevelopment\n \nof\n \nlife-saving\n \ntreatments\n \nfor\n \ncancer\n \npatients.\n "
}